HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model

Acta Virologica

Volumn 54, Issue 2, 2010, Pages 131-136

  Mahdavi, M ^a   Ebtekar, M ^a   Azadmanesh, K ^b   Khorramkhorshid, H R ^c,d   Rahbarizadeh, F ^a   Yazdi, M H ^e   Zabihollahi, R ^b   Abolhassani, M ^b   Hassan, Z M ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^d AVICENNA RESEARCH INSTITUTE   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Epitopes; Fusion peptide; HIV 1 p24 Nef; Immune response

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; P24 NEF FUSION PROTEIN; UNCLASSIFIED DRUG; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; NEF PROTEIN; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; P24 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; TH1 CELL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

AIDS VACCINES; ANIMALS; FEMALE; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77955856679     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2010_02_131     Document Type: Article

References (23)

1. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MN, Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgoz N, Draenert R, Stone DR, Brander C, Goulder PJ, Rosenberg ES, Altfeld M, Walker BD. (2003) Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77, 2081-2092.
2. Allen TM, Vogel TU, Fuller DH, Mothe BR, Steffen S, Boyson JE, Shipley T, Fuller J, Hanke T, Sette A, Altman JD, Moss B, McMichael AJ, Watkins DI. (2000) Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. 164, 4968-4978.
3. Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, Jackson SS, Lifton MA, Freed DC, Perry HC, Davies ME, Shiver JW, Letvin NL. (2002) Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J. Immunol. 168, 562-568.
4. Betts MR, Krowka JF, Kepler TB, Davidian M, Christopherson C, Kwok S, Louie L, Eron J, Sheppard H, Frelinger JA. (1999) Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS. Res. Hum. Retroviruses 15, 1219-1228.
5. Bolesta E, Gzyl J, Wierzbicki A, Kmieciak D, Kowalczyk A, Kaneko Y, Srinivasan A, Kozbor D. (2005) Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens. Virology 332, 467-479.
6. Calarota SA, Kjerrstrom A, Islam KB, Wahren B. (2001) Gene combination raises broad human immunodeficiency virusspecific cytotoxicity. Hum. Gene. Ther. 12, 1623-1637.
7. Coleman JK, Pu R, Martin M, Sato E, Yamamoto JK. (2005) HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection. Aids 19, 1457-466.
8. Couillin I, Letourneur F, Lefebvre P, Guillet JG, Martinon F. (2001) DNA vaccination of macaques with several different Nef sequences induces multispecific T cell responses. Virology 279, 136-145.
9. Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, Hudacik L, Whitney S, Keen T, Chou TH, Shen S, Joshi S, Kalyanaraman VS, Nair B, Markham P, Lu S, Pal R. (2006) Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 346, 151-168.
10. Currier JR, Visawapoka U, Tovanabutra S, Mason CJ, Birx DL, McCutchan FE, Cox JH. (2006) CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya use of multiple peptide sets increases the detectable breadth of the CTL response. BMC. Immunology 7, 8.
11. Gomez CE, Najera JL, Jimenez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, Wolf H, Liljestrom P, Wagner R, Esteban M. (2007) Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25, 1969-1992.
12. Gudmundsdotter L, Bernasconi D, Hejdeman B, Sandstrom E, Alaeus A, Lidman K, Ensoli B, Wahren B, Butto S. (2008) Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. Vaccine 26, 5182-5187.
13. Hamajima K, Fukushima J, Bukawa H, Kaneko T, Tsuji T, Asakura Y, Sasaki S, Xin KQ, Okuda K. (1997) Strong augment effect of IL-12 expression plasmid on the induction of HIV-specific cytotoxic T lymphocyte activity by a peptide vaccine candidate. Clin. Immunol. Immunopathol. 83, 179-84.
14. Jamali A, Mahdavi M, Hassan ZM, Sabahi F, Farsani MJ, Bamdad T, Soleimanjahi H, Motazakker M, Shahabi S. (2009) A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int. Immunology 21, 217-225.
15. Koopman G, Mortier D, Hofman S, Mathy N, Koutsoukos M, Ertl P, Overend P, van Wely C, Thomsen LL, Wahren B, Voss G, Heeney JL. (2008) Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J. Gen. Virol. 89, 540-553.
16. Liang X, Fu TM, Xie H, Emini EA, Shiver JW. (2002) Development of HIV-1 Nef vaccine components immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice. Vaccine 20, 3413-3421.
17. Pajot A, Schnuriger A, Moris A, Rodallec A, Ojcius DM, Autran B, Lemonnier FA, Lone YC. (2007) The Th1 immune response against HIV-1 Gag p24-derived peptides in mice expressing HLA-A02.01 and HLA-DR1. Eur. J. Immunol. 37, 2635-2644.
18. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Lu S, Markham P. (2005) Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J. Med. Primatol. 34, 226-236.
19. Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M et al.. (1995) High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69, 5838-5842.
20. Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ, Frey SE, Fuchs JD, Keefer MC, Lubeck MD, Egan M, Braun R, Eldridge JH, Haynes BF, Corey L. (2009) Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 27, 243-249.
21. Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B, Lockey TD, Zirkel A, Freiden P, Brown B, Surman S, Coleclough C, Slobod KS, Doherty PC, Hurwitz JL. (2005) Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine 23, 2454-2464.
22. Thakar MR, Bhonge LS, Lakhashe SK, Shankarkumar U, Sane SS, Kulkarni SS, Mahajan BA, Paranjape RS. (2005) Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef. J. Infect. Dis. 192, 749-759.
23. Tritel M, Stoddard AM, Flynn BJ, Darrah PA, Wu CY, Wille U, Shah JA, Huang Y, Xu L, Betts MR, Nabel GJ, Seder RA. (2003) Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J. Immunol. 171, 2538-2547.